Jefferies cuts Collegium Pharmaceutical stock price target on pain business concerns

Jefferies reduced its price target for Collegium Pharmaceutical (COLL) to $35 from $51, citing concerns about its pain business. The stock is down 45.66% year-to-date. The company reported Q3 2026 earnings, beating EPS estimates but meeting revenue expectations. Management plans to continue share buybacks and deleverage. Jefferies expects modest EBITDA growth by 2027, with ADHD business growth offsetting pain segment declines.

Original reporting
Published Nov 6, 2026, 9:28 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 9:43 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$COLL
Bearish
high confidence
Mentioned
$COLL
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$COLLBearishMed
01

Why it matters

The earnings beat provides limited upside, but the target reduction signals valuation concerns, likely keeping the stock under pressure.

02

Market read

The article delivers fresh earnings data and a new analyst price target, offering a medium‑term trading signal for COLL.

03

What to watch

Strong ADHD growth could offset pain segment weakness if sustained.

Relevance 7/10Novelty 7/10Timing: today

Background

Collegium Pharmaceutical reported Q3 2026 results with EPS beat and reaffirmed guidance, while Jefferies cut its price target due to concerns over the opioid pain business.

Company-level read

Ticker impact

$COLLBearishHigh confidence
Context

Jefferies lowered its price target on Collegium Pharmaceutical to $35 from $51 and reported the company's Q3 2026 earnings beat on EPS.

Expected impact

likely pressure as the market prices in the lower target and weak pain business outlook

Evidence & confidence

Analyst downgrade on valuation combined with modest earnings growth signals limited upside.

Market effects

Pain management segment may face continued scrutiny, affecting peers in the opioid space.

U.S. biotech sector sees modest impact from the target cut.

Limited to investors tracking small-cap pharma stocks.

Counterpoint

Buy rating remains unchanged; the lower target may present a buying opportunity at current levels.

Key entities

  • Collegium Pharmaceutical

    U.S.-listed pharmaceutical company focusing on ADHD and pain management.

  • Jefferies

    Equity research analyst firm that issued the price target cut.

Related articles

$COLLMedAI 8/10

Collegium Pharmaceutical Earnings Call Highlights ADHD Growth

Collegium Pharmaceutical (COLL) reported Q3 record revenue of $216.3M, up 3% YoY, driven by ADHD products (36% of total revenue). Jornay PM grew 24% YoY to $52M-$59.5M, while Azstarys saw 2% prescription growth. Pain portfolio revenue declined 9% YoY. Adjusted EBITDA fell 9% to $121.6M. The company reaffirmed 2026 guidance, expecting flat adjusted EBITDA.

$COLLMed

Collegium (COLL) Q3 2026 Earnings Call Transcript

Collegium (COLL) reported Q3 2026 net revenue of $216.3M, up 3% YoY. Jornay PM prescriptions grew 16% YoY, generating $59.5M in revenue. Azstarys revenue was $26.5M, with prescriptions up nearly 2% YoY. The company reaffirmed full-year guidance and announced a $50M share repurchase program.

$COLLMed

Collegium Pharmaceutical Q3 Earnings Call Highlights

Collegium Pharmaceutical reported Q3 revenue of $138M from its pain portfolio, with BELBUCA sales at $57.7M, XTAMPZA ER at $45.8M, and NUCYNTA at $30.8M. The company expects AZSTARYS prescription growth to accelerate in 2027 and reaffirmed its 2026 revenue forecast of $825M-$855M. It plans a $50M share repurchase and has $100M remaining under its authorization.

$COLLLow

Collegium Reports Third Quarter 2026 Financial Results; Reaffirms 2026 Guidance

COLLEGIUM PHARMACEUTICAL, INC (COLL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Collegium Reports Third Quarter 2026 Financial Results; Reaffirms 2026 Guidance – Generated Record Quarterly Net Revenues of $216.3 Million, Up 3% Year-over-Year – – Generated Record JORNAY PM ® Quarterly Net Revenue of $51.9 Million, Up 24% Year-over-Year – – Genera